The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Assessing Tumor Response to Therapy
Open accessAbstract
Most anticancer drugs are effective only in subgroups of patients, and our current understanding of tumor biology does not allow us to predict accurately which patient will benefit from a specific therapeutic regimen. Various techniques have, therefore, been developed for monitoring tumor response to therapy, but measuring tumor shrinkage on CT represents the current standard. Although response assessment on CT has been refined over many years, fundamental limitations remain. Interobserver variability in tumor size measurements is still high because of difficulties in delineating tumor tissue from secondary changes in the surrounding tissues. Furthermore, CT is inaccurate in differentiating viable tumor from necrotic or fibrotic tissue. Consequently, the degree of response may be underestimated on CT. Conversely, if tumor shrinkage is short lived and followed by rapid tumor regrowth, CT may overestimate the beneficial effects of a treatment. Finally, CT is limited in characterizing responses in tumors that do not change in size during therapy. Because the growth rate of untreated human tumors varies tremendously, an unchanged tumor size after some weeks of therapy may represent a drug effect but may also indicate a slowly growing tumor that was not affected by the applied therapy. Molecular imaging with PET and the glucose analogue (18)F-FDG PET has been shown to improve response assessment in several tumor types. In malignant lymphoma, international criteria for monitoring response to therapy have recently been revised, and the (18)F-FDG signal now plays a central role in defining tumor response. In a variety of solid tumors, single-center studies have indicated that (18)F-FDG PET may provide earlier or more accurate assessment of tumor response than CT, suggesting that (18)F-FDG PET could play a significant role in personalizing the treatment of malignant tumors. However, generally accepted criteria for response assessment in solid tumors are missing, which makes it frequently impossible to compare the results of different studies. International guidelines and criteria for response assessment by (18)F-FDG PET in solid tumors are, therefore, eagerly awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
RetractedNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“Despite enormous progress in medical imaging, the definition of tumor response has remained unchanged (3).”
BackgroundNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“Thus, the beneficial effect of erlotinib was apparently not restricted to patients achieving an objective response (35).”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079 · cited 2×
“This study randomized patients with advanced NSCLC to receive the EGFR kinase inhibitor gefitinib (Iressa; AstraZeneca) or placebo (37).”
BackgroundMethodVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Self-citationAllegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Lilja, H., Ulmert, D., & Vickers, A. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2351 · Cited by 921
Standards for PET Image Acquisition and Quantitative Data Analysis
Boellaard, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057182 · Cited by 902
Albain, K. S., Rusch, V. W., Crowley, J. J., Rice, T. W., Turrisi, A. T., Weick, J. K., Lonchyna, V. A., Presant, C. A., McKenna, R. J., & Gandara, D. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1880 · Cited by 856
Mazzaferri, E. L., Robbins, R. J., Spencer, C. A., Braverman, L. E., Pacini, F., Wartofsky, L., Haugen, B. R., Sherman, S. I., Cooper, D. S., Braunstein, G. D., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021702 · Cited by 654
Pao, W., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 631
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Wahl, R. L., Zasadny, K., Helvie, M., Hutchins, G. D., Weber, B., & Cody, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2101 · Cited by 605
Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 601
Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.-D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0272 · Cited by 494
Weber, W. A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C., & Schwaiger, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.004 · Cited by 493
Self-citationErasmus, J. J., Gladish, G. W., Broemeling, L., Sabloff, B. S., Truong, M. T., Herbst, R. S., & Munden, R. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.144 · Cited by 476
Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J., & Timothy, A. R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi272 · Cited by 401
Brücher, B. L. D. M., Weber, W., Bauer, M., Fink, U., Avril, N., Stein, H. J., Werner, M., Zimmerman, F., Siewert, J. R., & Schwaiger, M. (2001) · Annals of Surgery · doi:10.1097/00000658-200103000-00002 · Cited by 389
Self-citationHillner, B. E., Siegel, B. A., Liu, D., Shields, A. F., Gareen, I. F., Hanna, L., Stine, S. H., & Coleman, R. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5631 · Cited by 374
Use of PET for monitoring cancer therapy and for predicting outcome.
Weber, W. (2005) · PubMed · Cited by 341
Self-citationPlathow, C., & Weber, W. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045930 · Cited by 328
Self-citationBonomi, P. D., Finkelstein, D. M., Ruckdeschel, J. C., Blum, R. H., Green, M. D., Mason, B., Hahn, R., Tormey, D. C., Harris, J., & Comis, R. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1602 · Cited by 323
Swisher, S. G., Erasmus, J., Maish, M., Correa, A. M., Macapinlac, H., Ajani, J. A., Cox, J. D., Komaki, R. R., Hong, D., Lee, H. K., et al. (2004) · Cancer · doi:10.1002/cncr.20585 · Cited by 262
Definition of gross tumor volume in lung cancer: inter-observer variability
Van de Steene, J., Linthout, N., de Mey, J., Vinh-Hung, V., Claassens, C., Noppen, M., Bel, A., & Storme, G. (2002) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00453-4 · Cited by 255
Hoekstra, C. J., Stroobants, S. G., Smit, E. F., Vansteenkiste, J., van Tinteren, H., Postmus, P. E., Golding, R. P., Biesma, B., Schramel, F. J. H. M., van Zandwijk, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1189 · Cited by 247
Elkind, N. B., Szentpétery, Z., Apáti, A., Özvegy-Laczka, C., Várady, G., Ujhelly, O., Szabó, K., Homolya, L., Váradi, A., Buday, L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3303 · Cited by 225
PET/CT for Therapy Response Assessment in Lymphoma
Hutchings, M., & Barrington, S. F. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057190 · Cited by 220
de Geus-Oei, L.-F., Vriens, D., van Laarhoven, H. W. M., van der Graaf, W. T. A., & Oyen, W. J. G. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057224 · Cited by 207
Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W. H., Zijlstra, J. M., Bockisch, A., et al. (2008) · Blood · doi:10.1182/blood-2008-06-155820 · Cited by 204
Ishikawa, N., Daigo, Y., Takano, A., Taniwaki, M., Kato, T., Hayama, S., Murakami, H., Takeshima, Y., Inai, K., Nishimura, H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1556 · Cited by 194
PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma
Schöder, H., Fury, M., Lee, N., & Kraus, D. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057208 · Cited by 192
Kirkpatrick, P. N., Graham, J., & Muhsin, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1445 · Cited by 183
Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0344 · Cited by 182
Role of18F-FDG PET in Assessment of Response in Non–Small Cell Lung Cancer
Hicks, R. J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057216 · Cited by 149
Minn, H. R. I., Paul, R., & Ahonen, A. K. (1988) · PubMed · Cited by 142
Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy
Sharouni, S. Y. E., Kal, H. B., & Battermann, J. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601418 · Cited by 128
Pisters, K. M., Kris, M. G., Gralla, R. J., Zaman, M. B., Heelan, R. T., & Martini, N. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1757 · Cited by 122
Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer
de Geus‐Oei, L., van der Heijden, E. H. F. M., Visser, E. P., Hermsen, R., van Hoorn, B. A., Timmer-Bonte, J. N. H., Willemsen, A. T. M., Pruim, J., Corstens, F. H. M., Krabbe, P. F. M., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043414 · Cited by 121
Response to Therapy in Breast Cancer
Avril, N. E., Sassen, S., & Roylance, R. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057240 · Cited by 118
Lessons learned from independent central review.
Ford, R., Schwartz, L., Dancey, J., Dodd, L. E., Eisenhauer, E., Gwyther, S., Rubinstein, L., Sargent, D., Shankar, L., Therasse, P., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.031 · Cited by 117
The Role of 18F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries
Schwarz, J. K., Grigsby, P. W., Dehdashti, F., & Delbeke, D. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057257 · Cited by 111
Molecular Imaging in the Development of Cancer Therapeutics
Czernin, J. G., Weber, W., & Herschman, H. R. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.080904.190431 · Cited by 106
Self-citationBepler, G., Sommers, K. E., Cantor, A. B., Li, X., Sharma, A., Williams, C. C., Chiappori, A., Haura, E. B., Antonia, S. J., Tanvetyanon, T., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181874936 · Cited by 100
Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
Dunphy, M. P., & Lewis, J. S. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057281 · Cited by 94
Challenges in Projecting Clustering Results Across Gene Expression–Profiling Datasets
Lusa, L., McShane, L. M., Reid, J. F., Cecco, L. D., Ambrogi, F., Biganzoli, E. M., Gariboldi, M., & Pierotti, M. A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm216 · Cited by 92
Weber, W., Czernin, J. G., Phelps, M. E., & Herschman, H. R. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0982 · Cited by 83
Self-citationMonitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
Contractor, K. B., & Aboagye, E. O. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057273 · Cited by 81
Birchard, K. R., Hoang, J. K., Herndon, J. E., & Patz, E. F. (2009) · Cancer · doi:10.1002/cncr.24060 · Cited by 76
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
Krause, B. J., Herrmann, K., Wieder, H. A., & Büschenfelde, C. M. Z. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057232 · Cited by 71
Hoekstra, O., van Lingen, A., Ossenkoppele, G., Golding, R., & Teule, G. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00171020 · Cited by 27
Ramnath, N., Sommers, E., Robinson, L. A., Nwogu, C. E., Sharma, A., Cantor, A. B., & Bepler, G. (2005) · CHEST Journal · doi:10.1378/chest.128.5.3467 · Cited by 21
Cited by
Erlandsson, K., Buvat, I., Pretorius, P. H., Thomas, B. A., & Hutton, B. F. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/21/r119 · Cited by 733
Kinahan, P. E., & Fletcher, J. W. (2010) · Seminars in Ultrasound, CT and MRI · doi:10.1053/j.sult.2010.10.001 · Cited by 631
De Ruysscher, D., Faivre-Finn, C., Nestle, U., Hurkmans, C. W., Le Péchoux, C., Price, A., & Senan, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3271 · Cited by 364
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Kessler, L. G., Barnhart, H. X., Buckler, A. J., Choudhury, K. R., Kondratovich, M. V., Toledano, A., Guimaraes, A. R., Filice, R., Zhang, Z., Sullivan, D. C., et al. (2015) · Statistical Methods in Medical Research · doi:10.1177/0962280214537333 · Cited by 293
Metadata
- Authors
- Weber, W. A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2009-04-20
- Volume
- 50
- Issue
- Suppl 1
- Pages
- 1S-10S
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2115989405
- Cited by
- 269
- References
- 61
- FWCI
- 18.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.